Dr. Ledermann Discusses Patient Selection in Ovarian Cancer

Jonathan Ledermann, MD
Published Online: Tuesday, Jan 02, 2018



Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses patient selection in the treatment of patients with ovarian cancer.

It is important to delineate which patients benefit from BRCA-targeting agents. This is not only to keep costs down, but to ensure that the patients receiving the drug will derive the most benefit, Ledermann says.
 


Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses patient selection in the treatment of patients with ovarian cancer.

It is important to delineate which patients benefit from BRCA-targeting agents. This is not only to keep costs down, but to ensure that the patients receiving the drug will derive the most benefit, Ledermann says.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x